Preparation for treating primary biliary cholangitis and preparation method thereof
The traditional Chinese medicine prescription composed of corn silk and other drugs targets the damp heat and deficiency pathogenesis of primary bile cholangitis, and has achieved the effect of significantly improving the patient's symptoms and liver function indicators, solving the inaccurate efficacy and great side effects in the existing technology. The problem of high cost and the total effective efficiency is as high as 93.3%.
Patent Information
- Application Number
- CN202410144228.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-01
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-02-01
AI Technical Summary
The treatment of primary bile cholangitis has the problem of inaccurate efficacy, high side effects, high cost and ineffectiveness for 2/5 patients, and the treatment process is long and takes up a large amount of medical resources.
Traditional Chinese medicine prescriptions composed of corn squid, winter melon peel, coix seed, perilla, amomum villossus, moth, sea squid, turmeric, knotweed, chicken gizzard, uncaria gizzard, etc., are used to treat liver and gallbladder, spleen and dampness Method, design a preparation for the treatment of primary bile cholangitis, and treat damp heat and deficiency diseases through the combination of monarch and ministers.
Significantly improve the symptoms of jaundice, flank pain, fatigue, and sanitation in patients with primary bile cholangitis. The total effective clinical trials reached 93.3%, with few side effects, cheap prices, and saving medical resources.
Smart Images

Figure SMS_12 
Figure SMS_13 
Figure SMS_14
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cholangitis, and particularly relates to a preparation for treating primary biliary cholangitis and a preparation method thereof. Background Art
[0002] Primary biliary cholangitis is a chronic progressive autoimmune disease with unknown etiology. The pathological feature is chronic progressive non-suppurative interlobular cholangitis. Liver histological examination shows obvious portal inflammatory cell infiltration, interlobular cholangitis, disappearance of interlobular bile ducts, cholestasis, bile thrombosis, and bile debris necrosis around the portal area, which eventually leads to liver fibrosis and cirrhosis. Epidemiological data show that the median age of the disease is 62 years old. Its main clinical manifestations are fatigue and skin itching. Serum AMA antibody positivity is a specific diagnostic indicator for PBC. The average survival time after PBC diagnosis is 15 years. With the deepening of the understanding of the disease and the improvement of diagnostic technology, the incidence of the disease is increasing year by year, and it has become one of the common diseases that affect the quality of life and physical and mental health of the people.
[0003] The pathogenesis of primary biliary cholangitis is complex and has not yet been fully elucidated. It is generally believed that autoimmune factors, genetic susceptibility background, environmental factors and infectious factors are involved in the onset of the disease. At present, ursodeoxycholic acid is the only drug that is considered to have a certain effect on the disease, but it is still ineffective for 2 / 5 of primary biliary cholangitis patients. In the late stage, liver transplantation is often required, which takes up a lot of medical resources.
[0004] As the incidence of primary biliary cholangitis is on the rise, it has become a global public health issue. However, the treatment course of this disease is long and the cost is high. In addition, it has been found in clinical practice that the effect of using Western medicine alone is not particularly ideal. In addition, long-term use will increase the burden on the liver. Therefore, the role of this disease in treatment is limited, the clinical effect is uncertain, and the side effects limit its application in clinical practice. Traditional Chinese medicine treatment based on disease differentiation and syndrome differentiation is highly targeted, has few side effects, is cheap, and has significant efficacy. Its clinical application has been recognized by more and more doctors and patients. Summary of the invention
[0005] In order to overcome the above-mentioned defects of the prior art, the inventors have determined, after extensive research, that this disease belongs to the category of "jaundice" in traditional Chinese medicine. The etiology and pathogenesis of this disease are emotional distress, irregular diet, imbalance between work and rest, long-term illness and physical weakness, which cause the dysfunction of the spleen and stomach transportation and transformation functions, leading to the endogenous generation of dampness, which turns into heat over time. The dampness and heat are accumulated in the liver, leading to abnormal liver and gallbladder secretion, bile not following the normal path, overflowing from the skin and bladder, resulting in yellow body, yellow eyes, and yellow urine.
[0006] After extensive research, the inventor selected corn silk, wax gourd peel, coix seed, eupatorium, amomum villosum, desmodium, sea sand, curcuma, knotweed, chicken gizzard lining, and Uncaria rhynchophylla, and through the combination of monarch, minister, assistant and guiding herbs, the whole prescription has the effects of clearing the liver and gallbladder, strengthening the spleen and eliminating dampness, which is in line with the basic pathogenesis of primary biliary cholangitis with damp-heat in the liver and gallbladder and dampness stagnation in spleen deficiency.
[0007] The key improvement of the present invention is to adopt the treatment method of clearing liver and gallbladder, strengthening spleen and removing dampness for the dampness, heat and deficiency pathogenesis of the disease, and the prescription selection is based on the principle of definite efficacy, high safety, low price and convenient acquisition. Therefore, most of the drugs in the whole prescription are products of medicine and food, which ensure the safety and availability of the drugs while ensuring the efficacy. The corn silk commonly found in Henan Province is reused as the main drug in the prescription. The drug has the characteristics of convenient drug collection, low price, wide clinical application range, outstanding efficacy and small side effects. The coix seeds, amomum villosum, chicken gizzard lining and wax gourd peel that strengthen the spleen, remove dampness and reduce swelling in the prescription are products of medicine and food, with definite efficacy and high safety. All other drugs in the whole prescription have the characteristics of definite efficacy, low price, small side effects and easy acquisition, which greatly reduces the burden on patients and saves medical resources.
[0008] This prescription is composed of corn silk, wax gourd peel, coix seed, perilla, amomum villosum, centella asiatica, sea sand, curcuma, knotweed, chicken gizzard lining, Uncaria rhynchophylla and other drugs. Corn silk is used as the main drug in the prescription. This drug belongs to the liver and gallbladder, and has the effects of clearing the liver and gallbladder, promoting diuresis and reducing swelling. It is mainly used clinically to protect the liver, reduce jaundice and reduce swelling.
[0009] Winter melon peel belongs to the spleen, small intestine, and lung meridians, clears heat and removes dampness, and reduces swelling; coix seed belongs to the spleen and stomach meridians, strengthens the spleen, clears heat and removes dampness; perilla belongs to the spleen and stomach meridians, aromatically removes dampness, wakes up the spleen and stimulates appetite; Amomum villosum warms the spleen and removes dampness and stimulates appetite. The above four medicines mainly belong to the spleen and stomach meridians, have the effects of strengthening the spleen, clearing heat and removing dampness, and are clinically used to treat symptoms of spleen and stomach damage and dampness blocking the middle, and are collectively ministerial medicines.
[0010] Herba Lysimachiae belongs to the liver meridian and gallbladder meridian, has the effects of clearing away heat and detoxifying, removing dampness and relieving jaundice, and is mainly used to treat jaundice, edema, malaria, eczema, etc. Herba Lysimachiae, clearing away heat and detoxifying, promoting diuresis and removing dampness, is mainly used to treat hepatitis, etc. in clinical practice. Herba Curcumae, belongs to the liver and gallbladder meridian, promotes gallbladder and relieving jaundice, promotes qi and blood circulation, and is mainly used to treat jaundice, chest, abdomen, rib pain, etc. Herba Polygoni Cuspidati belongs to the liver and gallbladder meridian, has the effects of dispelling wind and removing dampness, and dispersing blood stasis, and is mainly used to treat damp-heat jaundice, etc. in clinical practice. Modern research shows that this medicine has a good effect on acute icteric hepatitis and neonatal jaundice. The above Herba Lysimachiae, Herba Lysimachiae, Herba Curcumae, and Herba Polygoni Cuspidati are adjuvants, mainly belonging to the liver and gallbladder meridian, have the effects of clearing away heat and removing dampness and relieving jaundice, and strengthen the power of the monarch medicine to clear away dampness and heat in the liver and gallbladder. In addition, it is assisted by the gizzard lining of chicken, belongs to the spleen and stomach meridians, and invigorates the stomach and promotes digestion, so as to avoid excessive heat clearing of various medicines and hurting the spleen and stomach.
[0011] A small amount of Uncaria rhynchophylla is used in the formula, which can make all the drugs return to the liver meridian and achieve the effect of clearing liver heat. The whole formula has the effects of clearing liver and gallbladder, strengthening spleen, clearing heat and removing dampness through the combination of monarch, minister, assistant and envoy, which is in line with the basic pathogenesis of primary biliary cholangitis, liver and gallbladder dampness and heat, spleen deficiency and dampness stagnation.
[0012] To this end, the present invention adopts the following technical solutions:
[0013] A preparation for treating primary biliary cholangitis is designed, comprising the following raw materials in parts by weight: 50-70 parts of corn silk, 20-40 parts of wax gourd peel, 20-40 parts of coix seeds, 10-20 parts of perilla, 3-9 parts of amomum villosum, 20-40 parts of desmodium herba, 20-40 parts of sea sand, 10-20 parts of turmeric, 10-20 parts of knotweed, 10-20 parts of chicken gizzard lining, and 1-5 parts of Uncaria rhynchophylla.
[0014] Furthermore, a preparation for treating primary biliary cholangitis is designed, which is composed of the following raw materials, calculated by weight: 55-65 parts of corn silk, 25-35 parts of wax gourd peel, 25-35 parts of coix seed, 12-18 parts of perilla, 4-8 parts of amomum, 25-35 parts of desmodium herb, 25-35 parts of sea sand, 12-18 parts of curcuma, 12-18 parts of knotweed, 15-25 parts of chicken gizzard lining, and 2-4 parts of Uncaria rhynchophylla.
[0015] Preferably, it is composed of the following raw materials, by weight: 60 parts of corn silk, 30 parts of wax gourd peel, 30 parts of coix seed, 15 parts of eupatorium, 6 parts of amomum, 30 parts of desmodium, 30 parts of sea sand, 15 parts of curcuma, 15 parts of knotweed, 20 parts of chicken gizzard lining, and 3 parts of Uncaria rhynchophylla.
[0016] The present invention further provides a method for preparing the above preparation, wherein the raw materials are weighed according to the weight portions, crushed to 100-150 meshes respectively, blended and mixed evenly, and made into granules or capsules.
[0017] Furthermore, the method further comprises the following steps:
[0018] (1) mixing the crushed Lygodium japonicum powder, Polygonum cuspidatum powder, Gallus galli powder, and Uncaria rhynchophylla powder, and extracting the mixture by ethyl acetate extraction to obtain a first extract and medicinal residues;
[0019] (2) drying the medicinal residue and mixing it with the remaining raw material powder, extracting it by water extraction to obtain a second extract;
[0020] (3) The first extract is mixed with the second extract after removing the solvent, and then concentrated and granulated.
[0021] Preferably, in the step (1), the material-liquid ratio of the ethyl acetate extraction method is 1 g: 4-6 mL; the extraction temperature is 70-80° C.; and the extraction time is 1-2 h.
[0022] Preferably, in step (2), the material-liquid ratio of the water extraction method is 1 g: 8-10 mL; the extraction temperature is 90-100° C.; and the extraction time is 1-2 h.
[0023] Compared with the prior art, the beneficial technical effects of the present invention are:
[0024] The present invention gives full play to the advantages of TCM syndrome differentiation and treatment and overall regulation in the treatment of primary biliary cholangitis. According to the different individual syndromes and combined with the patient's constitution, the overall treatment is combined with syndrome differentiation and treatment, which is highly targeted, has outstanding efficacy, few side effects, is easily accepted by patients, and has high compliance. The Chinese medicine is mainly processed from Chinese medicinal materials, and the selected Chinese medicinal materials all meet the requirements of the "Pharmacopoeia", have no obvious toxic and side effects, and are highly accessible, easy to make, easy to use, low in price, and highly practical. The whole recipe can clear the liver and gallbladder, strengthen the spleen and eliminate dampness. Through clinical observation, it can significantly improve the clinical symptoms of jaundice, hypochondriasis, fatigue, poor appetite, etc. in patients with primary biliary cholangitis. Clinical trials have found that this recipe can effectively improve the indicators of bilirubin, alkaline phosphatase, glutamyl transpeptidase, alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglycerides, etc. in patients with primary biliary cholangitis, and the total effective rate is 93.3%. DETAILED DESCRIPTION
[0025] The specific implementation modes of the present invention are described below in conjunction with examples. However, the following examples are only used to illustrate the present invention in detail and are not intended to limit the scope of the present invention in any way.
[0026] Example 1: A preparation for treating primary biliary cholangitis, composed of the following raw materials: 60g of corn silk, 30g of wax gourd peel, 30g of coix seed, 15g of eupatorium, 6g of amomum, 30g of desmodium herb, 30g of sea sand, 15g of curcuma, 15g of knotweed, 20g of chicken gizzard lining, and 3g of Uncaria rhynchophylla.
[0027] Example 2: A preparation for treating primary biliary cholangitis, comprising the following raw materials: 50g of corn silk, 40g of wax gourd peel, 20g of coix seed, 20g of eupatorium, 3g of amomum, 40g of desmodium, 20g of sea sand, 10g of curcuma, 20g of knotweed, 10g of chicken gizzard lining, and 5g of Uncaria rhynchophylla.
[0028] Example 3: A preparation for treating primary biliary cholangitis, comprising the following raw materials: 70g of corn silk, 20g of wax gourd peel, 20g of coix seed, 0g of eupatorium, 9g of amomum, 20g of desmodium herb, 40g of sea sand, 10g of curcuma, 10g of knotweed, 30g of chicken gizzard lining, and 1g of Uncaria rhynchophylla.
[0029] Example 4: A preparation for treating primary biliary cholangitis, composed of the following raw materials: 55g of corn silk, 35g of wax gourd peel, 25g of coix seed, 12g of eupatorium, 4g of amomum, 35g of desmodium herb, 35g of sea sand, 18g of curcuma, 12g of knotweed, 25g of chicken gizzard lining, and 4g of Uncaria rhynchophylla.
[0030] Example 5: A preparation for treating primary biliary cholangitis, composed of the following raw materials: 65g of corn silk, 25g of wax gourd peel, 35g of coix seed, 18g of eupatorium, 8g of amomum, 25g of desmodium herb, 25g of sea sand, 12g of curcuma, 18g of knotweed, 15g of chicken gizzard lining, and 2g of Uncaria rhynchophylla.
[0031] Example 6: A method for preparing a preparation for treating primary biliary cholangitis. The raw materials are weighed according to the weight described in Example 1, crushed into 120 meshes respectively, blended and mixed, and made into granules or capsules.
[0032] Embodiment 7: A method for preparing a preparation for treating primary biliary cholangitis, based on Embodiment 6, further comprising the following steps:
[0033] The crushed Lygodium japonicum powder, Polygonum cuspidatum powder, Gallus gallus endometrium powder and Uncaria rhynchophylla powder are mixed and extracted by ethyl acetate extraction to obtain a first extract and medicinal residues; the material-liquid ratio of the ethyl acetate extraction method is 1g:6mL; the extraction temperature is 80°C; and the extraction time is 1h.
[0034] The medicinal residue is dried and mixed with the remaining raw material powder, and extracted by water extraction to obtain a second extract; the material-liquid ratio of the water extraction method is 1g:8mL; the extraction temperature is 90°C; and the extraction time is 2h.
[0035] The solvent is removed from the first extract and then mixed with the second extract, followed by concentration and granulation.
[0036] Case 1
[0037] Patient: Fang Moumou, female, 24 years old, first diagnosed on April 9, 2022.
[0038] Chief complaint: Yellowing of body and eyes for more than a year.
[0039] Current medical history: One year ago, the patient began to experience yellowing of the body and eyes without obvious cause, accompanied by fatigue, drowsiness, bitter and sticky mouth, poor appetite, sticky stools, and yellow urine. The symptoms recurred repeatedly.
[0040] Tongue and pulse: The tongue is red, the tongue coating is yellow and greasy, there are teeth marks on the edges, and the pulse is slippery and rapid.
[0041] Auxiliary examination: Color Doppler ultrasound: diffuse liver damage, liver function: ALT67U / L, AST56U / L, ALP310U / L, GGT189U / L, TBIL82umol / L, DBIL52umol / L, TBA58umol / L. AMA1:160, AMA-M2 positive, four infectious diseases: negative.
[0042] TCM diagnosis: jaundice caused by damp-heat in the liver and gallbladder, and spleen deficiency and dampness stagnation.
[0043] Western medicine diagnosis: primary biliary cholangitis
[0044] Treatment method: Clear the liver and gallbladder, strengthen the spleen and eliminate dampness.
[0045] Prescription: The preparation in Example 1, 10 packs, decocted in water, 1 pack per day.
[0046] Second visit: April 20, 2022. The patient's yellow eyes and body, fatigue were relieved, and appetite increased. After taking another 14 doses, the symptoms of yellow eyes and body and fatigue were significantly improved, appetite was good, and bowel movements were normal. The original prescription was continued for 21 doses.
[0047] Third visit: May 13, 2022. The patient's fatigue symptoms improved, appetite was normal, bowel movements were normal, and the yellowing of the body and eyes was significantly reduced. Liver function test: ALT31U / L, AST24U / L, ALP110U / L, GGT53U / L, TBIL32umol / L, DBIL19umol / L, TBA18umol / L.
[0048] Case 2
[0049] Patient: Mr. Li, male, 30 years old, first visited the hospital on July 8, 2022.
[0050] Chief complaint: Yellowing of body and eyes for more than 3 months.
[0051] Current medical history: The patient developed jaundice of the body and eyes, bitter taste in the mouth, irritability, poor appetite, fatigue, constipation, and yellow urine after fatigue 3 months ago. The patient did not receive relevant treatment and the symptoms recurred.
[0052] Tongue and pulse: The tongue is red, with a thin yellow and greasy coating, teeth marks on the edges, and a rapid pulse.
[0053] Auxiliary examination: Color Doppler ultrasound: diffuse liver damage, liver function: ALT58U / L, AST46U / L, ALP290U / L, GGT140U / L, TBIL79umol / L, DBIL46umol / L, TBA51umol / L. AMA1:180, AMA-M2 positive, four infectious diseases: negative.
[0054] TCM diagnosis: jaundice caused by damp-heat in the liver and gallbladder, and spleen deficiency and dampness stagnation.
[0055] Western medicine diagnosis: primary biliary cholangitis
[0056] Treatment method: Clear the liver and gallbladder, strengthen the spleen and eliminate dampness.
[0057] Prescription: The preparation in Example 1, 14 packs, decocted in water, 1 pack per day.
[0058] Second visit: On July 22, 2022, the patient's jaundice was relieved, fatigue improved, appetite recovered, and bowel movements improved. After taking another 30 doses, the patient's jaundice, fatigue, and poor appetite improved, appetite was good, and bowel movements were normal. Re-examination of the liver, gallbladder, spleen, and pancreas showed no abnormalities, and re-examination of liver function showed ALT24U / L, AST16U / L, ALP90U / L, GGT41U / L, TBIL28umol / L, DBIL17umol / L, and TBA11umol / L.
[0059] Case 3
[0060] Patient: Yuan Moumou, female, 52 years old, first diagnosed on October 9, 2022.
[0061] Chief complaint: Yellowing of body and eyes for more than 2 years.
[0062] Current medical history: Two years ago, the patient developed yellowing of the body and eyes, bitter taste in the mouth, sweating, fatigue, dry stool, and yellow urine without obvious cause. Color Doppler ultrasound examination at the local hospital showed liver cirrhosis and abnormal liver function. The patient repeatedly visited the local hospital and took liver protection drugs, but the symptoms recurred.
[0063] Tongue and pulse: The tongue is red, the tongue coating is yellow and greasy, there are teeth marks on the edges, and the pulse is slippery and rapid.
[0064] Auxiliary examination: Color Doppler ultrasound: cirrhosis, splenomegaly. Liver function: ALT61U / L, AST52U / L, ALP350U / L, GGT180U / L, TBIL91umol / L, DBIL62umol / L, TBA67umol / L. AMA1:120, AMA-M2 positive, four infectious diseases: negative.
[0065] TCM diagnosis: jaundice caused by damp-heat in the liver and gallbladder, and spleen deficiency and dampness stagnation.
[0066] Western medicine diagnosis: primary biliary cholangitis
[0067] Treatment method: Clear the liver and gallbladder, strengthen the spleen and eliminate dampness.
[0068] Prescription: The preparation prepared in Example 6, 3 capsules per day, taken for 14 days.
[0069] Second visit: On October 24, 2022, the patient's yellow eyes and fatigue improved, his appetite recovered, and his bowel movements became normal. After taking 21 doses, all symptoms of the patient disappeared. Liver function tests showed ALT35U / L, AST22U / L, ALP101U / L, GGT62U / L, TBIL35umol / L, DBIL19umol / L, and TBA14umol / L.
[0070] Case 4
[0071] Patient: Chen Moumou, female, 34 years old, first visit on 2022.10.11.
[0072] Chief complaint: Yellowing of body and eyes for 5 months.
[0073] Current medical history: The patient developed yellowing of the body and eyes, bitter and sticky mouth, fatigue, drowsiness, yellow urine, and dry stool after exertion 5 months ago. No attention was paid to it or treatment was given.
[0074] Tongue and pulse: The tongue is red, the tongue coating is thick yellow, there are teeth marks on the edges, and the pulse is slippery and rapid.
[0075] Auxiliary examination: Color Doppler ultrasound: diffuse liver damage. Liver function: ALT78U / L, AST62U / L, ALP287U / L, GGT134U / L, TBIL76umol / L, DBIL42umol / L, TBA34umol / L. AMA1:160, AMA-M2 positive, four infectious diseases: negative.
[0076] TCM diagnosis: jaundice caused by damp-heat in the liver and gallbladder, and spleen deficiency and dampness stagnation.
[0077] Western medicine diagnosis: primary biliary cholangitis
[0078] Treatment method: Clear the liver and gallbladder, strengthen the spleen and eliminate dampness.
[0079] Prescription: Take the preparation prepared in Example 6, 3 capsules per day, for 10 days.
[0080] Second visit: On October 22, 2022, the patient's yellow eyes and fatigue were significantly relieved, his appetite increased, and his bowel movements were normal. 21 doses of the original prescription.
[0081] Third visit: On November 13, 2022, the patient's symptoms were completely cured. Liver function test showed ALT41U / L, AST26U / L, ALP92U / L, GGT45U / L, TBIL36umol / L, DBIL16umol / L, TBA11umol / L.
[0082] Case 5
[0083] Patient: Fan Moumou, female, 57 years old, first diagnosed on March 2, 2022.
[0084] Chief complaint: Yellowing of body and eyes for 4 months.
[0085] Current medical history: The patient developed yellowing of the body and eyes after eating 4 months ago, accompanied by dry and bitter mouth, sweating, irritability, fatigue, yellow urine, and dry stool. No attention was paid to it or treatment was given.
[0086] Tongue and pulse: red tongue, yellow and greasy coating, stringy and rapid pulse.
[0087] Auxiliary examination: Liver function: ALT54U / L, AST41U / L, ALP310U / L, GGT198U / L, TBIL69umol / L, DBIL47umol / L, TBA41umol / L. AMA1:120, AMA-M2 positive, four infectious diseases: negative.
[0088] TCM diagnosis: jaundice caused by damp-heat in the liver and gallbladder, and spleen deficiency and dampness stagnation.
[0089] Western medicine diagnosis: primary biliary cholangitis
[0090] Treatment method: Clear the liver and gallbladder, strengthen the spleen and eliminate dampness.
[0091] Prescription: The preparation prepared in Example 7, 3 capsules per day, taken for 14 days.
[0092] Second visit: On March 17, 2022, the patient's jaundice and fatigue improved, his appetite recovered, and his bowel movements became normal. 20 doses of the original prescription.
[0093] Third visit: On April 8, 2022, the patient called after taking the medicine. All symptoms were relieved. The color Doppler ultrasound showed no abnormalities in the liver, gallbladder, spleen and pancreas. The liver function test showed ALT41U / L, AST26U / L, ALP92U / L, GGT45U / L, TBIL36umol / L, DBIL16umol / L, TBA11umol / L. Consultation on lifestyle adjustments. Avoid greasy, raw, cold, spicy and stimulating food.
[0094] Case 6
[0095] Patient: Yuan Moumou, female, 26 years old. First visit on November 7, 2022.
[0096] Chief complaint: Yellowing of body and eyes for 2 years.
[0097] Current medical history: The patient developed yellowing of the body and eyes after activities 2 months ago, accompanied by bitter taste in the mouth, irritability, fatigue, drowsiness, poor appetite, frequent dreams at night, yellow urine, and dry stools. The patient was examined at the local hospital outpatient clinic for abnormal liver function and was given Danfei Liganing and polyene phosphatidylcholine capsules orally, but the symptoms did not improve.
[0098] Tongue and pulse: red tongue, yellow and greasy coating, stringy and rapid pulse.
[0099] Auxiliary examination: Color Doppler ultrasound: diffuse liver damage. Liver function: ALT68U / L, AST46U / L, ALP368U / L, GGT186U / L, TBIL92umol / L, DBIL62umol / L, TBA56umol / L. AMA1:120, AMA-M2 positive, four infectious diseases: negative.
[0100] TCM diagnosis: jaundice caused by damp-heat in the liver and gallbladder, and spleen deficiency and dampness stagnation.
[0101] Western medicine diagnosis: primary biliary cholangitis
[0102] Treatment method: Clear the liver and gallbladder, strengthen the spleen and eliminate dampness.
[0103] Prescription: The preparation in Example 1, 14 packs, decocted in water, 1 pack per day.
[0104] Second visit: On November 22, 2022, the patient's yellow eyes and fatigue were alleviated, appetite and sleep improved, bowel movements were once every 1-2 days, and urination was normal. 20 packs of the original prescription.
[0105] Third visit: On December 13, 2022, the patient's yellow eyes and fatigue were significantly improved, his appetite basically returned to normal, his sleep was significantly improved, his bowel movements were once a day, the quality was good, and his urination was normal. 20 packs of the original prescription.
[0106] Four examinations: On January 3, 2023, the patient's symptoms basically disappeared, his appetite and sleep were good, his stool was soft, once a day, and his urination was normal. Liver function was rechecked: ALT32U / L, AST18U / L, ALP102U / L, GGT56U / L, TBIL32umol / L, DBIL12umol / L, TBA15umol / L. Color Doppler ultrasound showed no abnormality. The original prescription was decocted in water for consolidation treatment.
[0107] Clinical trial example:
[0108] 1. Observation object
[0109] All cases in this study were from the outpatient and inpatient departments of the Department of Spleen, Gastroenterology and Hepatobiliary Diseases of the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from January 2021 to December 2022. They met the diagnostic criteria for primary biliary cholangitis, aged between 18 and 65 years old, regardless of gender. Among them, there were 13 males and 17 females in the treatment group, with an average age of 40.82±12.87 years and an average course of disease of 3.21±1.71 years; there were 12 males and 18 females in the control group, with an average age of 41.11±12.68 years and an average course of disease of 3.12±1.52 years; the independent sample t test and χ2 test showed that there was no statistically significant difference in gender, age, course of disease, and condition between the two groups (P>0.05).
[0110] 2. Design
[0111] This study adopted a randomized controlled design and selected 60 patients with primary biliary cholangitis who met the criteria of this study. The number of patients in the treatment group and the control group was allocated in a 1:1 ratio, with 30 patients in each group. Patients were numbered according to the order in which they visited the hospital. Odd-numbered patients were assigned to the control group, and even-numbered patients were assigned to the observation group.
[0112] 3. Diagnostic criteria
[0113] Refer to "Management of Primary Biliary Cirrhosis. American Association for the Study of Liver Diseases Diagnosis and Treatment Guidelines":
[0114] ① Serum biochemical changes related to cholestasis: elevated levels of alkaline phosphatase (ALP) and glutamyl transpeptidase (CGT) with no other explanation (B-ultrasound examination: normal biliary system), positive anti-mitochondrial antibodies (AMA) (titer ≥1:40) or positive AMA-M2 subtype, can basically confirm PBC; ② For those with negative AMA or AMA-M2, anti-nuclear antibodies (ANA), anti-smooth muscle antibodies and immunoglobulin tests should be performed, and liver biopsy should be consistent with PBC pathological changes.
[0115] 4. Case inclusion criteria
[0116] ①Meet the above diagnostic criteria;
[0117] ②Age 20 to 65 years old;
[0118] ③ No other diseases such as heart, brain, kidney, etc.
[0119] ④No other immune system diseases
[0120] ⑤B-ultrasound showed no signs of decompensated cirrhosis, such as portal hypertension and peritoneal effusion;
[0121] ⑥ Patient informed consent
[0122] 5. Case Exclusion Criteria
[0123] Those with concurrent viral hepatitis, long-term drinking, exposure to poisons, or taking drugs that cause liver damage;
[0124] Patients with terminal complications such as infection, massive gastrointestinal bleeding, large amounts of refractory ascites, hepatorenal syndrome, and hepatic encephalopathy;
[0125] Patients with combined tumors and severe heart, kidney and other systemic organ diseases;
[0126] Pregnant or breastfeeding women;
[0127] PBC-AIH overlap syndrome;
[0128] Those with allergies or known allergies to this type of prescription drug;
[0129] Participating in or currently participating in other drug clinical trials in the last 3 months.
[0130] 6. Treatment options
[0131] The observation group was given the Chinese medicine of Example 1 of the present invention for decoction. The medicine was taken in a conventional way, 1 pack per day, for a course of 3 months.
[0132] The control group was given tauroursodeoxycholic acid capsules (Taorote, 250 mg per capsule), 15 mg / (kg·d), orally after meals, for 3 months.
[0133] 7. Observation indicators and effect evaluation criteria
[0134] 7.1 Observation indicators
[0135] Before and at the end of treatment, the liver function of the two groups of patients were tested: ALP, GGT, TBIL, ALT, AST, TC, TG, and the improvement of patients' symptoms was recorded.
[0136] 7.2 Effect evaluation criteria
[0137] Refer to the "Clinical Guidance for New Traditional Chinese Medicines" of the State Food and Drug Administration to formulate the efficacy evaluation of each indicator, and observe and analyze the relationship between various efficacy standards.
[0138] Markedly effective: clinical symptoms are significantly improved or disappear, symptom scores are reduced by more than 70%, and liver function recovers by more than 70%;
[0139] Effective: clinical symptoms are significantly improved or disappear, symptom scores are reduced by more than 30%, and liver function recovers by more than 50%;
[0140] Ineffective: The condition does not improve or worsens after treatment.
[0141] 8. Safety evaluation
[0142] Level 1: safe, without any adverse reactions;
[0143] Level 2: relatively safe. If there are adverse reactions, no treatment is required and the drug can continue to be administered.
[0144] Level 3: There are safety issues and moderate adverse reactions, but the drug can continue to be administered after treatment;
[0145] Level 4: The trial was terminated due to adverse reactions.
[0146] 9. Experimental Statistical Processing
[0147] Statistical analysis software: SPSS19.0 software package was used for data analysis. All statistical tests were two-sided tests, and P ≤ 0.05 was considered to be statistically significant.
[0148] Balance analysis of basic values: Use analysis of variance or χ2 test to compare demographic data and other basic value indicators to measure the balance between the two groups.
[0149] Analysis of measurement data of different groups: Mean ± standard deviation was used for statistical description, and group t test was used to compare the differences between the two groups.
[0150] The count data of different groups were described statistically using frequency and median, and the χ2 test or nonparametric test was used.
[0151] 10. Results
[0152] 10.1 Comparison of changes in blood alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels between the two groups of patients before and after treatment
[0153]
[0154] Note: ★: Compared with the observation group before treatment P >0.05; △: comparison between before and after treatment within the same group P <0.05; ■: compared with the control group after treatment P <0.05.
[0155] 10.2 Comparison of total bilirubin (TBIL), alkaline phosphatase (ALP), and glutamyl transpeptidase (GGT) levels between the two groups before and after treatment
[0156]
[0157] Note: ★: Compared with the observation group before treatment P >0.05; △: comparison between before and after treatment within the same group P <0.05; ■: compared with the control group after treatment P <0.05.
[0158] 10.3 Comparison of changes in total cholesterol (TC) and triglyceride (TG) levels in the two groups of patients before and after treatment
[0159]
[0160] Note: ★: Compared with the observation group before treatment P >0.05;△Comparison between before and after treatment within the same group P <0.05; ■: compared with the control group after treatment P <0.05.
[0161] 10.4 Comparison of clinical efficacy between the two groups before and after treatment
[0162]
[0163] 11. Adverse Reactions
[0164] During the observation process, 3 cases of adverse reactions occurred in the observation group, including 1 case of nausea and 2 cases of diarrhea; 15 cases of adverse reactions occurred in the control group, including 4 cases of nausea, 8 cases of diarrhea, and 1 case of skin itching.
[0165] 12. Conclusion
[0166] From the above statistical results, it can be seen that the observation group and the control group have significant differences in reducing TBIL, ALP, GGT\ALT, AST, TC, TG, etc. The clinical efficacy of the two groups of patients is compared, and the total effective rate of the observation group is higher than that of the control group. The results show that the Chinese medicine composition for treating fatty liver of the present invention has significant efficacy compared with the control group.
[0167] The present invention has been described in detail above in conjunction with the embodiments; however, those skilled in the art will appreciate that, without departing from the concept of the present invention, the specific parameters in the above embodiments may be changed to form a plurality of specific embodiments, which are all within the common variation range of the present invention and will not be described in detail one by one.
Claims
1. A preparation for treating primary biliary cholangitis, characterized in that: The invention is composed of the following raw materials in parts by weight: 50-70 parts of corn silk, 20-40 parts of wax gourd peel, 20-40 parts of coix seeds, 10-20 parts of eupatorium, 3-9 parts of amomum villosum, 20-40 parts of schizonepeta tenuifolia, 20-40 parts of sea sand, 10-20 parts of turmeric, 10-20 parts of knotweed, 10-30 parts of chicken gizzard lining and 1-5 parts of Uncaria rhynchophylla.
2. A preparation for treating primary biliary cholangitis, characterized in that: The drug substance is composed of the following raw materials, calculated by weight: 55-65 parts of corn silk, 25-35 parts of wax gourd peel, 25-35 parts of coix seeds, 12-18 parts of eupatorium, 4-8 parts of amomum villosum, 25-35 parts of desmodium herb, 25-35 parts of sea sand, 12-18 parts of turmeric, 12-18 parts of polygonum cuspidatum, 15-25 parts of chicken gizzard lining, and 2-4 parts of Uncaria rhynchophylla.
3. The preparation according to claim 2, characterized in that, The drug composition is composed of the following raw materials, calculated by weight: 60 parts of corn silk, 30 parts of wax gourd peel, 30 parts of coix seeds, 15 parts of eupatorium, 6 parts of amomum villosum, 30 parts of desmodium herb, 30 parts of sea sand, 15 parts of curcuma, 15 parts of polygonum cuspidatum, 20 parts of chicken gizzard lining, and 3 parts of Uncaria rhynchophylla.
4. A method for preparing a preparation for treating primary biliary cholangitis according to any one of claims 1 to 3, characterized in that: The raw materials are weighed according to the weight proportions, crushed into 100-150 meshes respectively, blended and evenly mixed, and made into granules or capsules.
5. The preparation method according to claim 4, characterized in that: The following steps are also included: (1) mixing the crushed Lygodium japonicum powder, Polygonum cuspidatum powder, Gallus galli powder, and Uncaria rhynchophylla powder, and extracting the mixture by ethyl acetate extraction to obtain a first extract and medicinal residues; (2) drying the medicinal residue and mixing it with the remaining raw material powder, extracting it by water extraction to obtain a second extract; (3) The first extract is mixed with the second extract after removing the solvent, and then concentrated and granulated.
6. The preparation method according to claim 5, characterized in that: In the step (1), the material-liquid ratio of the ethyl acetate extraction method is 1 g: 4-6 mL; the extraction temperature is 70-80° C.; and the extraction time is 1-2 h.
7. The preparation method according to claim 5, characterized in that: In the step (2), the material-liquid ratio of the water extraction method is 1 g: 8-10 mL; the extraction temperature is 90-100° C.; and the extraction time is 1-2 h.
